Wilson Sonsini Goodrich & Rosati has advised Edgewise Therapeutics on the transaction. McDermott Will & Schulte has advised Servier. White & Case has advised Servier on...
Edgewise Therapeutics Sells Muscular Dystrophy Business and Sevasemten to Servier for up to $2.65 Billion
Owkin Completes Carve-Out and $33 Million Series A Financing for Waiv
McDermott Will & Schulte and Owkin’s in-house legal team have advised Owkin. Owkin has completed the carve-out of Waiv, formerly known as Owkin Dx, and secured...
Sagard NewGen Announces Minority Investment in Quipment
McDermott Will & Schulte has advised Sagard NewGen. Sagard NewGen has completed a minority investment in Quipment, a prominent provider of equipment solutions for clinical trials,...
MaaT Pharma Completes €9 Million Capital Increase Through Share Offering
McDermott Will & Schulte has advised MaaT Pharma. MaaT Pharma has announced the successful completion of a capital increase totaling approximately €9 million. The transaction comprised...
H.A.C. Pharma Acquires Global Rights to ESBRIET® from Roche
McDermott Will & Schulte has advised H.A.C. Pharma on the deal. H.A.C. Pharma, a French pharmaceutical company, has acquired the worldwide rights, excluding the United States,...
LATTICE MEDICAL Raises €43 Million in Series B Financing Round
McDermott Will & Schulte has advised LATTICE MEDICAL. LATTICE MEDICAL, a French medtech company specializing in tissue engineering, has completed a €43 million Series B financing...
Adcytherix Closes €105 Million Series A Fundraising Round
McDermott Will & Emery has advised Adcytherix. Adcytherix, a biopharmaceutical company focused on the design and development of proprietary antibody-drug conjugates (ADCs), has successfully closed a...
EverZom Secures €10 Million Financing Round for Development of Exosome-Based Therapies
McDermott Will & Schulte has advised EverZom. EverZom has completed a €10 million financing round to advance its work on innovative exosome-based therapies targeting inflammatory and...
Servier Acquires Menin Inhibitor BN104 from BioNova
McDermott Will & Schulte has advised Servier on the acquisition of BN104 from BioNova. Servier, an international, independent pharmaceutical group governed by a foundation, has completed...
MaaT Pharma Licenses European Rights to Xervyte for aGvHD to Clinigen
McDermott Will & Emery has advised MaaT Pharma. MaaT Pharma has entered into an exclusive long-term license and distribution agreement with Clinigen for its therapy Xervyte...
Comac Medical Group Acquires ILIFE Consulting
McDermott Will & Emery advised ILIFE Consulting on the transaction. ILIFE Consulting, a contract research organization company (CRO) specializing in the early-stage development of oncology and...
Pierre Fabre’s R&D Collaboration and License Agreement with RedRidge Bio
McDermott Will & Emery advised Pierre Fabre on the deal. Pierre Fabre announced an exclusive R&D collaboration and license agreement with RedRidge Bio to identify and...